Procter & Gamble Health Ltd delivered exceptional fourth-quarter results for FY26, with net profit rising 54.6% year-on-year to ₹94.6 crore from ₹61.2 crore in the corresponding quarter last year. According to reports from CNBC TV18, the pharmaceutical company's revenue increased 19.1% to ₹371 crore from ₹311 crore, demonstrating robust top-line growth. The company's EBITDA surged 67.6% to ₹135.6 crore from ₹80.9 crore a year ago, while the EBITDA margin expanded sharply to 37% from 26%, indicating significant operational efficiency improvements.
The board recommended a final dividend of ₹45 per equity share for FY26, as reported by CNBC TV18. Including the interim and special dividend declared earlier in the year, the total dividend payout for FY26 stands at ₹205 per share. The final dividend, subject to shareholder approval, will be paid on or before September 25, 2026. For the full financial year FY26, the company reported revenue from operations of ₹1,408 crore compared to ₹934.2 crore in the previous financial year, while annual net profit rose to ₹326.9 crore from ₹234.4 crore year ago.
P&G Health posted a profit before tax of ₹133.2 crore during the quarter, compared with ₹78.5 crore in the year-ago period, according to CNBC TV18. The company's total expenses increased to ₹241.2 crore from ₹235.6 crore year ago, largely due to higher employee benefits and other operating expenses. Shares of the company ended 1.12% lower at ₹5,662 ahead of the Q4 earnings result announcement on Tuesday, May 26. The stock has gained 9.4% over the last month, but has declined more than 1% year-to-date. The company continues to operate as a single reportable segment focused on pharmaceuticals.
P&G Health noted that the implementation of the new labour codes from November 2025 is not expected to have a material financial impact based on its current assessment, as reported by CNBC TV18. The company maintains its focus on pharmaceutical operations as its primary business segment. The strong quarterly performance reflects the company's operational excellence and strategic positioning in the pharmaceutical sector, with significant margin expansion and revenue growth demonstrating effective business execution.
